Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECI830 alone and with ribociclib + endocrine therapy in advanced HR+/HER2- breast cancer and CCNE1-amplified solid tumors
jRCT2031250117Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of ECI830 in breast cancer and Nonhematologic neoplasms (6 arms), sponsored by Novartis. Primary endpoints: Incidence of dose-limiting toxicities (DLTs), Incidence of adverse events (AEs) and serious adverse events (SAEs) and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
ECI830
03
Conditions
breast cancerNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031250117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250117.